Summa Health CEO resigns after physician vote of no confidence

Thomas Malone, MD, president and CEO of Akron, Ohio-based Summa Health, has resigned from his position weeks after 240 Summa physicians called for his departure with a vote of no confidence.

The vote came after Malone had decided to terminate the contract of Summa Emergency Associates (SEA), the emergency physicians who had providing care in Summa Akron City Hospital, on Dec. 31. They were replaced with a new group, U.S. Acute Care Physicians, which according to the Akron Beacon Journal, is run by the husband of a Summa physician who had inside knowledge of the negotiations with SEA.

In a statement, Summa board chair Jim McIlvaine praised Malone for making “significant progress” at the system since he took over in 2015, not mentioning the public rift between the administration and physicians.

“We deeply appreciate that Tom made this difficult decision because he believes it is the right step forward for Summa Health, our employees, our physicians and the patients we serve,” McIlvaine said. “In our recent conversations with Tom it became apparent that his continued presence in his role at CEO was distracting the forward progress of the organization.”

In a shorter statement, Malone repeated the concerns about being a distraction, saying such a situation was “unacceptable” to him.

“I appreciate each member of the Summa Health family that has been with me on this journey over the last two years. Together, we have made great strides in moving the organization forward. I thank every one of them and will root for Summa Health’s continued success.”

The departure, however, doesn’t appear to mean a change for the emergency physician contract. McIlvaine said the staffing decision is “final and will remain unchanged.”

The Beacon Journal reported word of Malone’s exit was welcomed by many at Akron City hospital, with one unidentified nurse trying to give a reporter a high five.

Jeff Wright, MD, president of SEA, said the group would be willing to negotiate a new deal once the new CEO is in place.

“[We] would love to work with the Summa board to correct what has happened, to bring back the same level of care we offered the community for four decades,” Wright said. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.